“Most pancreatic cancer will not respond to immune checkpoint inhibitors [ICIs] as a single agent, so we have been wondering if we can convert the pancreatic cancer tumor microenvironment from a cold one to a hot one,” Lei Zheng, MD, PhD, of the Johns Hopkins University School of Medicine in Baltimore, Maryland, and presenter of the study, said. The purpose of this study was to determine if GVAX could prime the tumor microenvironment to be more responsive to ICIs. Read more . . .
Urelumab, an anti-CD137 agonist antibody, plus nivolumab and a GVAX vaccine, showed some preliminary activity as a neoadjuvant therapy for resected pancreatic cancer, though further studies are needed to determine clinical benefit, according to preliminary results of a study presented at the virtual Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting & Preconference Programs (SITC 2020).